Moteur de recherche d’entreprises européennes
Financement de l’UE (2 068 409 €) : Amélioration de l’efficacité de l’édition du génome (IMGENE) Hor08/08/2017 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Amélioration de l’efficacité de l’édition du génome (IMGENE)
CRISPR genome editing technology is considered to become the greatest technological improvement in biomedical research since the invention of the polymerase chain reaction 25 years ago and pharmaceutical companies as well as academic research are eager to apply it. However, the efficiency of introducing defined changes into the genome by CRISPR is still low, currently limiting its application in basic research, industry and gene therapy. IMGENE unites expert European research groups of academia and industry to address by innovative and complementary approaches the low efficiency of precise genome editing using CRISPR technology. To our best knowledge, IMGENE is the only concerted approach to tackle the important problem of low genome editing efficiency of CRISPR in a multidisciplinary, intersectorial manner. The IMGENE consortium consisting of 6 academic and 1 industrial beneficiary (AstraZeneca), 2 industrial partners (Taconic; MilliporeSigma), and the patient organization Genetic Alliance, aims to improve the genome editing efficiency of CRISPR by research training of 8 ESRs to unleash the full potential of this technology. Combining complementary knowledge on protein chemistry, molecular biology, cellular biology, viral vectors, transgenic mice, gene therapy, and bioinformatics present in the network, IMGENE will establish novel tools and protocols for improved CRISPR genome editing efficiency that will be of immediate benefit for health and life science research, the pharmaceutical industry, and the application of gene therapy. In addition, IMGENE addresses crucial ethical questions related to the application of genome editing technology in animals, plants, and humans, which have to be solved to gain acceptance by the society. By excellent research training of 8 ESRs on a scientifically and economically highly relevant topic and additional training in transferable skills, IMGENE will educate novel leaders with great career perspectives in industry and academia.
| Genetic Alliance UK Ltd. | ? |
| Academisch Ziekenhuis Leiden | 255 374 € |
| Astrazeneca AB | 263 659 € |
| Instituto de Biologia Molecular e Celular-Ibmc | 238 356 € |
| Kobenhavns Universitet | 580 164 € |
| Max Delbrueck Centrum Fuer Molekulare Medizin IN DER Helmholtz-Gemeinschaft (MDC) | 249 216 € |
| Universitaetsklinikum Freiburg | 249 216 € |
| Ustav Molekularni Genetiky AV CR V.V.I. | 232 422 € |
https://cordis.europa.eu/project/id/765269
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Genetic Alliance UK Ltd., Bristol, Royaume Uni.